

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 8-K

MEDICIS PHARMACEUTICAL CORP

Form 8-K

August 19, 2003

=====

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): August 18, 2003

Medicis Pharmaceutical Corporation
(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

0-18443
(Commission File
Number)

52-1574808
(IRS Employer
Identification No.)

8125 North Hayden Road
Scottsdale, Arizona
(Address of Principal
Executive Offices)

85258-2463
(Zip Code)

Registrant's telephone number, including area code:

(602) 808-8800

N/A

(Former Name or Former Address, if Changed Since Last Report)

=====

Item 7. Financial Statements and Exhibits

(a) Financial Statements of Business Acquired.

Not Applicable.

(b) Pro Forma Financial Information.

Not Applicable.

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 8-K

(c) Exhibits.

99.1 Copy of press release, dated August 18, 2003, issued by Medicis Pharmaceutical Corporation

Item 9. Regulation FD Disclosure

On August 18, 2003, Medicis Pharmaceutical Corporation issued a press release announcing the anticipated closing of the exchange offer for its new 1.5% Contingent Convertible Senior Notes due 2033 on August 19, 2003 and the impact of the exchange offer on its financial statements. A copy of the press release appears as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDICIS PHARMACEUTICAL
CORPORATION
(Registrant)

Date: August 19, 2003

/s/ Mark A. Prygocki, Sr.

Name: Mark A. Prygocki, Sr.
Title: Executive Vice President,
Chief Financial Officer,
Corporate Secretary and
Treasurer

EXHIBIT INDEX

EXHIBIT NUMBER -----	DESCRIPTION -----
99.1	Copy of press release, dated August 18, 2003, issued by Medicis Pharmaceutical Corporation